Davis Polk advised the sales agent on the offering. IDEAYA Biosciences, Inc. executed its common stock for up to an aggregate amount of $90 million. Based…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
